Conversely, VZV AI values overlapped between both groups, re-confirming that AIs do not discriminate between a virus-driven and a polyspecific intrathecal immune response.
A comparison was also carried out between the control group (re-inoculated with untreated tumor) and trial group (re-inoculated with oxaliplatin pre-treated tumor), producing similar results.
More than a third of patients in both groups had been re-hospitalized between 2 and 7 years post-injury.
One study commented on staged patellar re-surfacing for persistent patellofemoral symptoms, and described no differences between both groups.
Re-differentiation in scaffold cultures diminished these differences, demonstrating that only 17 genes related to skeletal development were significantly differentially expressed between both groups.
It implied diminishing MRS between both groups.
Third, SvO2 appeared different between both groups.
Patient characteristics were similar between both groups.
All parameters were compared between both groups.
There was no heterogeneity between both groups.
There was no difference between both groups.
